A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523908-75-00

Enrollment

Registered

2026-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Brief summary

Change from baseline in CPET peak VO2

Detailed description

Change from baseline in ECV (subgroup)., Change from baseline in NT-proBNP., Change from baseline in KCCQ-CSS.

Interventions

DRUGPlacebo for ALXN2220

DRUGWainzua 45 mg solution for injection in pre-filled pen

DRUGRecombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in CPET peak VO2	—

Secondary

Measure	Time frame
Change from baseline in ECV (subgroup)., Change from baseline in NT-proBNP., Change from baseline in KCCQ-CSS.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 21, 2026